Figure 4

Angiogenic capability of HUVECs is affected by OATP2A1. Tube formation by HUVECs was measured in the CM from human colorectal cancer LoVo cells, which were incubated in Ham’s F-12 for 24 h (a). HUVECs were incubated with fresh medium (stripe) or the CM in the absence (as control, open) or the presence of indomethacin (10 µM, diamond), mixture of EP antagonists (AH6809; 10 µM, AH23848; 25 µM, hatched), BSP (10, 25, or 100 µM, closed), or all agents (grey) on Matrigel® for 4 h. Tube formation assay was observed in HUVECs knocked-down for SLCO2A1 (b). Wound healing assay of HUVECs untreated (as control, open) or treated with PGE₂ (50 nM, check) in the absence or presence of mixture of EP antagonists (AH6809; 10 µM and AH23848; 25 µM, hatched), BSP (25 µM, closed), or the both (grey) for 10 h (c). Experiments were repeated at least three times with triplicate, and each point represents results with the mean ± SEM. (n = 3). *, ** and *** indicate significant difference in tube length from by Student’s t-test with p < 0.05, <0.01 and <0.001, respectively.